- According to new research, a technique for reading the genetic abnormalities in patient tumors with a simple blood test has passed a critical test of accuracy and reliability.
- One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending congestive heart failure (CHF) finds improved health outcomes but suggests that less frequent screening than currently recommended may yield similar clinical benefit.
Tags: ChildhoodCancer, Survivorship
- Scientists at Dana-Farber Cancer Institute have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal disease.
Tags: Antibody, BasicResearch
- A study 10 years ago discovered a gene mutation that could be treated by a drug that was on the market for something else and changed the way lung cancer patients are treated. It was the start of the era of precision medicine in lung cancer and transformed treatment of the disease.
Tags: EGFR, LungCancer, TargetedTherapy
- Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a targeted drug for advanced stomach cancer.
Tags: chemotherapy, TargetedTherapy
- A team of researchers led by Dana-Farber Cancer Institute investigators has uncovered a connection between people with Down syndrome and having a heightened risk of developing acute lymphoblastic leukemia (ALL) during childhood.
Tags: BasicResearch, Leukemia
- Dana-Farber researchers have received a three-year, $1.2 million research grant from Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation to lead a team in developing and testing new vaccines for patients with cancers linked to the human papillomavirus (HPV).
Tags: Grants, HeadNeckCancers, GynecologicCancers
- Investigators at Dana-Farber led by Leena Gandhi, MD, PhD, report a promising way of predicting which patients with non-small cell lung cancer (NSCLC) are most likely to benefit from a drug that frees up an immune system attack on tumor cells.
Tags: LungCancer, Immunotherapy
- Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer, according to a new study from scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and McGill University. The findings, published in Nature Genetics, identify potential new targets for drug treatments.
Tags: ChildhoodCancer, Genomics, TargetedTherapy, BrainTumors
- Beginning this summer, Dana-Farber Cancer Institute will provide hematology and medical oncology care under a new agreement at St. Elizabeth's Medical Center, a part of the Steward Health Care System.
Showing 31-40 of 520 items